Podcasts about imodium

Rover's fastest lap, tipping, and how to improve the shizzy. The Today show interviewed AI actress Tilly Norwood. Mitch McConnell is alive. The 3rd rail on the subway. Taylor Swift hanging out with Tom Cruise at Chiefs vs. Broncos game. Car influencer James Wehr was killed in a car crash after his McLaren struck tree and burst into flames. Duji had a man fly out to Chicago to meet him then denied him. Are Rover and Duji still in love? An Australian athlete at the Hyrox Pro race defecated on herself during the competition. Krystle understands why Rover needs Imodium. Duji felt bad for a woman she saw puking. JLR video calls the show. How often are you using the bidet? Krystle is having her roof fixed. What would you dress up as for comic con? Rover went to the eye doctor. See omnystudio.com/listener for privacy information.

How was Rover's dinner date? Duji is on Imodium as well. JLR got reprimanded for talking to Ashley in sales. Police officer gets a ride from an Uber driver to chase after a suspect.See omnystudio.com/listener for privacy information.

Rover is sick, suns out guts out, ice throwing, and AC usage. Duji finally got her Kalm bracelet and ring. NFL player Josh Allen upset that the news has been talking about the death of Ed Oliver's son. Deshawn Watson is upset that Browns fans boo him. Enes Kanter kicked out of a Chicago Sky game. Most expensive piece of NBA game memorabilia. Does Duji wear makeup? Update to the 16-year-old girl who ran out onto the football field. Contracted surrogate carrying a baby with a heart defect refused to abort the child. How was Rover's dinner date? Duji is on Imodium as well. JLR got reprimanded for talking to Ashley in sales. Police officer gets a ride from an Uber driver to chase after a suspect. Krystle and JLR have a sit-up competition. Courtney Stodden is now calling out Dr. Drew. A 'wanted' poster put up in Georgia over a man picking up $30 he found on the ground. See omnystudio.com/listener for privacy information.

How was Rover's dinner date? Duji is on Imodium as well. JLR got reprimanded for talking to Ashley in sales. Police officer gets a ride from an Uber driver to chase after a suspect.

Rover is sick, suns out guts out, ice throwing, and AC usage. Duji finally got her Kalm bracelet and ring. NFL player Josh Allen upset that the news has been talking about the death of Ed Oliver's son. Deshawn Watson is upset that Browns fans boo him. Enes Kanter kicked out of a Chicago Sky game. Most expensive piece of NBA game memorabilia. Does Duji wear makeup? Update to the 16-year-old girl who ran out onto the football field. Contracted surrogate carrying a baby with a heart defect refused to abort the child. How was Rover's dinner date? Duji is on Imodium as well. JLR got reprimanded for talking to Ashley in sales. Police officer gets a ride from an Uber driver to chase after a suspect. Krystle and JLR have a sit-up competition. Courtney Stodden is now calling out Dr. Drew. A 'wanted' poster put up in Georgia over a man picking up $30 he found on the ground. 

  Caregiving can feel painfully slow. The same responsibilities, struggles, and prayers continue day after day. But slow does not mean aimless. In this episode, I draw from the careful adjustments required for Gracie's new prosthetic legs. A body shaped by decades of trauma cannot be corrected overnight. Neither can a life. God understands what has shaped us, knows exactly what He is correcting, and works with a wisdom that never hurries and never wastes time. I also celebrate eight years of Hope for the Caregiver on American Family Radio, share a small-town Montana story involving our postmaster and an urgent request for Imodium, and return to Ecclesiastes 3:11 with the caregiver hymn of the week, "In His Time." When progress seems glacial and caregiving appears endless, I keep returning to what is true: God makes all things beautiful in His time.

IT'S BEEN A WEEK!!! Lizz and Moji have been chugging Imodium the last seven days as they follow the twists and turns of the Fifth Circus Court ruling that created a federal ban and put the mail distribution of the abortion pill mifepristone on the chopping block. Between Sam Alito giving us a week of reprieve to dial back our panic to 23/7 and the FDA assessing the fate of abortion medication using a debunked “study” (really just a forced-birth fever dream scribbled on fishwrap), we were already hanging by a thread. Then Oklahoma decided to do the absolute most by funneling money to FAKE clinics. So yeah, you're gonna need an emotional support drink, spliff, snack, or whatever survival instincts you have left for this episode.   GUEST ROLL CALL:   We had to call in backup for this one! We are joined by Michigan-based OGBYN PA-C, Author, and Creator, Nikki Sapiro Vinckier – the ultimate reproductive health sherpa! Nikki is going to talk about her new book, “We Deserve More,” her latest citizen-led repro win in Michigan, and guide us through EVERYTHING that is happening to access to medication abortion right now. Can we still get pills? How do we get pills? What pills can we still get? Will Sam Alito give me pills? WE NEED ANSWERS, AND NIKKI IS DELIVERING!   PLUS! THE ONE AND ONLY, RaeShanda Lias is here and queeeeer, babay! The absolutely fabulous Digital Creator & Diversity Advocate joins the Buzzkills to fill our joy cups back up by making us laugh, reminding us that Black queer love is indeed thriving, talking to us about clapping back online, her new podcast, and checking the board about RFK Jr. being absolute trash. You're welcome.   Times are heavy, but knowledge is power, y'all. We gotchu.   OPERATION SAVE ABORTION: You can still join the 10,000+ womb warriors fighting the patriarchy by clicking HERE for past Operation Save Abortion trainings, your toolkit, marching orders, and more.   HOSTS: Lizz Winstead IG: @LizzWinstead Bluesky: @LizzWinstead.bsky.social Moji Alawode-El IG: @Mojilocks Bluesky: @Mojilocks.bsky.social   SPECIAL GUESTS: Nikki Sapiro Vinckier IG: @NikkiVinck Bluesky: @NikkiVinck.bsky.social RaeShanda Lias IG: @RaeShanda_Lias / @itsreallyverysimplepodcast TikTok: @shopaif   GUEST LINKS: Nikki's Website BUY: Nikki's New Book, “We Deserve More: Why Reproductive Healthcare Is Broken And What You Can Do About It” Take Back Trust RaeShanda's Website RaeShanda's TikTok   NEWS DUMP: Secret Service Officer Arrested for Indecent Exposure in Miami After Trump Golf Event Member of Trump's Secret Service Arrested Senate Committee Approves Bill to Pay Out-Of-State Groups With Oklahoma Choosing Childbirth Southwest Airlines Finally Pays Flight Attendant Nearly $1 Million After 9-Year Abortion Case Louisiana Says Men Are Spiking Women's Drinks With Abortion Pills. There's Scant Evidence of That. Josh and Erin Hawley's ‘Love Life Initiative' Signals a New Phase of the Antiabortion Fight With Legal Briefs In, Supreme Court Weighs Telehealth Access for the Abortion Pill Facebook Took Down Lizz's Post Talking About Abortion  TROLL JOSH HAWLEY'S HOTLINE: (202) 224-6154   EPISODE LINKS: ADOPT-A-CLINIC: Choices Rising 6 DEGREES: Bette Midler, Sarah Jessica Parker and Kathy Najimy to Run Amok in ‘Hocus Pocus 3' SUBSTACK: Abortion Access Front Operation Save Abortion Expose Fake Clinics BUY AAF MERCH! EMAIL your abobo questions to The Feminist Buzzkills AAF's Abortion-Themed Rage Playlist   FOLLOW US: Listen to us ~ FBK Podcast  Instagram ~ @AbortionFront Bluesky ~ @AbortionFront TikTok ~ @AbortionFront Facebook ~ @AbortionFront YouTube ~ @AbortionAccessFront   TALK TO THE CHARLEY BOT FOR ABOBO OPTIONS & RESOURCES HERE! PATREON HERE! Support our work, get exclusive merch and more!  DONATE TO AAF HERE! ACTIVIST CALENDAR HERE! VOLUNTEER WITH US HERE! ADOPT-A-CLINIC HERE! GET ABOBO PILLS FROM PLAN C PILLS HERE! When BS is poppin', we pop off! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

„Dneska můžeš natočit písničku na mobil. Tak proč ještě existují studia?“Touto otázkou odstartoval Honza Vedral devátou Headliner půdu, která se tentokrát věnovala nahrávání, produkci a životu za sklem studia. Pozvání přijali Milan Cimfe ze studia Sono, Michal „Amák“ Šťastný z Golden Hive a Tomáš Fröde z kapely Imodium a studia I.Mluvilo se o tom, proč jsou studia pořád důležitá, proč se kapely ve studiu rozpadají, proč je zpěv nejkřehčí část nahrávání i o tom, jak vznikaly desky Lucie, Kabátu nebo Alice. Došlo i na LSD ve studiu, rozbité zuby při produkci, nebo na to, proč je někdy lepší nechat nahrávku nedokonalou.„Hudba jsou vzpomínky a emoce. Lidem je často úplně jedno, že to hraje blbě, ale stalo se to jednou správně,“ zaznělo během večera plného zkušeností i historek z praxe.Záznam první části Headliner půdy končí akustickou písní Tomáše Frödeho. Druhá část vás čeká již brzy. A vy jste srdečně zváni na další Headliner půdu už 25.5. v Malostranské besedě s tématem "manažerky". O své zkušenosti se přijdou podělil Ludmila "Dydla" Karlíková, která se stará o Vypsanou fixu, Kateřina Žbirková či Rozálie. Projekt Headliner půda vzniká za podpory OSA a Ministerstva kultury.

In Episode 5, Chris chats to the official marathon pace team ahead of the Bunbury 3 Waters Festival on Sunday 12th April 2026. As part of our discussions with Bunbury Runners Club last year during the planning phase for 2026, we agreed to aid the club in sourcing pacers for the marathon which would be a first for the event. We have: - Joel Gray and Chris Shaw steering the coveted 3hr bus, - the reliable Ashlee 'Ritto' Ritson and Uncle Audwin Lee for 3hr30 - Jake Beacock and Noah Simpson with their casio watches calibrated for the 4hr bus, and - Vici Richardson and Bryan Bourke singing and yapping for 4hr30 straight. From Joel's 150g/hr carbs consumption, Ritto's family discount, Audwin's $60 unofficial marathon, Jake's Imodium obsession, Vici's feet post Herdys and Bryan's love of Yokine Reserve, we get to learn more about our marathon pacers and what draws them to the marathon and what makes them weapons in their own right.    This episode is brought to you by the Bunbury 3 Waters Running Festival. Famous for its beautiful, flat, and fast course, the Bunbury 3 Waters Running Festival offers ocean views up Ocean Drive, dolphin spotting in Koombana Bay, fast racing around Big Swamp and the challenge of the infamous Bunbury lighthouse - or as we like to call it - THE CHECKERED BASTARD. With personalised drink stations, on-course entertainment, and a finish line vibe that captures everything great about the regional WA running community, the Bunbury 3 Waters Running Festival delivers an experience you'll remember long after your legs stop aching. So lace up, set your sights south, and make Bunbury your next race destination in April 2026. Find out more at runbunbury.com.au Reach out and connect! Instagram: @warunningpod Email: warunningpodcast@gmail.com  Strava: https://www.strava.com/clubs/WARP  

Spida and Producer George had a rap battle bet for the Cowboys vs Titans NRL game. Cowboys win and Spida must write and perform a Titans rap. For a man without rhythm, it’s no easy feat! Liam found one his favourite events ever on the weekend – a knitting festival “Knitopia.” He was looking for a gift for Leisel and then something jumped out at him! The crocheted “Positivity Peen”. It is exactly what it sounds like and Leisel couldn’t be more stoked. Leisel puts the boys to the test with parental threats & Spida has obviously had his fair of sprays, because he is remarkably good at finishing the phrase! If the Positivity Peen was not embarrassing enough, Leisel had a trip to the chemist on the weekend to keep the medicine cabinet stocked. She likes to be prepared for any occasion and needed to stock up on Imodium in case things ever went bad. Worst case scenario – the pharmacist selling her the diarhoea medication was a stud! No amount of explaining can save you in that interaction!See omnystudio.com/listener for privacy information.

Katie, Sean, Cal & Dave chat with two Stockport Harriers who have couple running goals perfected. Steve has PBs of 5K - 20:30, 10k - 42:00, half marathon- 1:32:00, marathon 3:15. Sarah has PBs of 5K 20:35, 10k- 42:00 , half marathon 1:33:00, marathon- 3:20:00. Sarah talks about how she did her first race in 2018 and it went perfectly, then she goes on to run marathons in the majors. Sarah ran Berlin Marathon in 3:23 and she did this off training on a static bike and watching Netflix. Sarah is approaching her 55th birthday and she talks about her mindset change and how she wants to get an England Masters Vest again. Sarah also discusses her issues with gels and how its cause her stomach issues and the need for the toilet. She shares her story of using Imodium. Steve discusses how in 2022, he had a feeling that he would be PBing in all distances. He was very confident at the beginning of races and it worked, but why? Steve has a long dislike for the half in the Tour of Tameside so he tells us what he wants to do with it. Both Steve and Sarah talk about the the Majors and how marathons are their races. Pacing is a big thing, and they get to Pace at the Rome Marathon.This episode is in collaboration with @jamesmolesrunningcoaching James has been coaching experienced runners and those getting into running for over 7 years. From weekly and monthly session planning, advice on nutrition and race day prep as well as strength sessions specific to runners, James offers a range of services to help support you be the best runner you can be. For more info, visit James Moles running coaching on socials.

(00:00-13:02) Happy Birthday Daddy Yankee. Does Daddy Padre have a song? Nevin Shapiro still can't get past this National Championship loss. But he does love him some Mario Cristobal. TJ Oshie talking about being traded from St. Louis to Washington and how that hurt. A caller called into a Syracuse basketball show and asked the coach who he expected to replace him when he gets fired.(13:10-24:52) Boots Randolph. Pants right below your breast bone. E-Mail of the Day.(25:02-29:45) Please.....like me. Text your wife directly for the Imodium. Spring Training finna be a pony.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It's 2026, and Jane and Fi are back - reunited and ready to run their mouths. In this episode, they demonstrate their budding potential as high-level film critics. There's chat about hair transplants, Imodium, and the WoolOvers debate is reopened… then firmly closed. There's also conversation surrounding grief and loss.Recommendations you'll hear in this episode: 'The Thinking Game' documentary, 'Gabriel's Moon' and 'The Predicament' by William Boyd, 'A Schooling in Murder' by Andrew Taylor, and musician Jesse Welles' 'Join Ice' song. Our most asked about book is called 'The Later Years' by Peter Thornton. You can listen to our 'I'm in the cupboard on Christmas' playlist here: https://open.spotify.com/playlist/1awQioX5y4fxhTAK8ZPhwQ If you want to contact the show to ask a question and get involved in the conversation then please email us: janeandfi@times.radio Follow us on Instagram! @janeandfiPodcast Producers: Eve SalusburyExecutive Producer: Rosie Cutler Hosted on Acast. See acast.com/privacy for more information.

Daniel Buitrago, Brandon Fifield & Jack Lau invite special guest Konnor in studio to chat with the AWP crew and share his compelling story about a career in law enforcement, commercial fishing and the guide life in Kodiak, Alaska   Client expectations, the raft is finally put away, flex tail air pumps, shout out to AK Gun Co., Screamer Captains, Ermine Skates & The Nordic skating update, Mateos broken finger, Rocky Mountain Elk Hunt “The Pinnacle” of North American big game hunting, New goat & sheep tags available, Kodiak goat situation, Kodiak Brown Bears language, the haws that got away, passing on the first day what you'd  take on the last day, Processing fish in Homer, police work in Minnesota, purpose working in law-enforcement, emotional perspective in law-enforcement training, transition to guiding in Alaska, Transporting for black bear and a 250 lbs halibut, the hunt'n fool boys, the Alaskan Cross Fox, correcting bear behavior, carrying a cannon, client fitness variations and the conversations, scout to hunt ratio, Kodiak Beach Billes, wilderness EMT's certs, treating for advanced care, (Quick Clott, Turn-icate, Imodium & Tums), Peak Re-Fuel favorites, the power of beach jerky, opitomoa   Visit our website - www.alaskawildproject.com Watch on YouTube - www.youtube.com/@alaskawildproject Follow on Instagram - www.instagram.com/alaskawildproject $upport on Patreon - www.patreon.com/alaskawildproject

My Story   Talk 29  Travels in Asia and Africa My first trip outside of Europe or America was in 1986 when I visited Pakistan, India, Singapore, Malaysia and Indonesia. It came about in a quite remarkable way. One Sunday in 1985 I was reading an article about India in a Christian magazine when quite unexpectedly I had the distinct impression that the Lord was going to send me to India. I told Eileen about it and we agreed to wait and see what would happen. The very next Wednesday evening we had a meeting in the College chapel where the guest speaker was Ray Belfield who had come to challenge the students about overseas missions. After the meeting Ray came round to our house for a hot drink before making the return journey back to Wigan. As we prayed together just before he left, I found myself praying that the Lord would show us how best we as a College could support the work of missions, and the moment I had finished Ray said to me,             I'll tell you what you can do. You can go to India. I had told him nothing about what had happened the previous Sunday, so this seemed to be a real confirmation of what I felt the Lord had been telling me. But how would I raise the airfare? Shortly after that, Bob Stevenson was the speaker at a similar Wednesday evening meeting, and at the end of his message he totally surprised me. He said to the students, Now the Principal doesn't know I'm going to do this. In fact, I haven't asked anyone's permission to do so, but I want us to take an offering now. It's for your Principal's airfare to India. And the airfare was covered. The following January I went to India. In fact it was not just India. That month I visited Pakistan, Singapore, Malaysia and Indonesia as well. I travelled first to Pakistan and preached for a weekend in Karachi. This was my first experience outside of Europe or America and the culture shock was massive. And it wasn't helped by a severe attack of sickness and diarrhoea! I was so grateful that my friend Dr John Tonge had told me to pack some Imodium tablets! As a result, I was able to preach but sadly unable to eat any of the wonderful food they offered me. On the Monday I flew on to India with an empty stomach but soon recovered very quickly. I landed in Bombay (now Mumbai) and flew on to Coimbatore in the province of Tamil Nadu where AoG missionaries, Lawrence and Margaret Livesey, had planted churches decades earlier. It was truly wonderful to see the results of their sacrificial labours. I spent a little over two weeks there, preaching, teaching and visiting orphanages and schools run by the churches. David Prakasam and Lawrence Arumanayagam had both been students at Mattersey and were now training others to plant churches. One of the greatest thrills of my trip was to visit some of the many churches that had been planted by the students of our students. I saw very clearly that what we were doing at Mattersey was following Paul's instruction to Timothy in 2 Timothy 2:2. The rest of my trip was spent in short visits to Singapore, Malaysia, and Indonesia. I was based with Cyril and Barbara Cross, British AoG missionaries in Singapore, who looked after me very well. Before I flew back home I had the privilege of preaching in Bible College chapel in Kuala Lumpur, a large AoG church in Singapore, and a very lively house group led by an eighteen-year-old girl in Medan, Indonesia. If I had ever had doubts about women's ministry in the past, that girl's anointed leadership gift was more than enough to change my mind. My final trip to countries beyond Europe while we were still at Mattersey was to Burkina Faso in the year 2000. Several of our students at Mattersey had come from that part of Africa, formerly known as the Upper Volta. Like our students from India, most of them came on full scholarships which we provided for them. The first of these was Guetawende Roamba, the student I mentioned earlier who had recognised that a woman speaking in tongues in a College rally in Manchester was speaking in Moré, his own native language. Another, who came a few years later, was Philippe Ouédraogo who when he first arrived at Mattersey couldn't speak a word of English. I remember picking him up at Retford Station and speaking to him in French, giving him his first English lesson on the ten-minute journey back to College. Passing a field of cows, I pointed at them and said, les vaches, en anglais, COWS. Not that that piece of information would be much help for his studies at Mattersey! But it was a start, and Philippe became remarkably proficient in English in just a few weeks. It was through him that we received the invitation to visit Burkina Faso in November 2000. Eileen was very much looking forward to coming with me but unfortunately was prevented from doing so at the last minute. Eileen had retired in 1999 after serving as College Matron for 21 years and was at home in the utility room doing some decorating. As she was putting up a frieze she climbed onto the washing machine to help her reach the top of the wall and losing her balance fell off it backwards onto the hard floor, breaking the top of her arm close to the shoulder. On hearing the news I was home within minutes – our house was in the College grounds – and rushed her to A&E who confirmed the fracture and strongly advised her not to make the trip to Africa. And when I arrived there a few days later and experienced travelling on their bumpy roads, it was clear that we had made the right decision. The leaders in Ouagadougou were so impressed that she had let me come that they sent me home a few days earlier than planned. The highlights of the trip were preaching several times in French at the National Pastors' Conference, having a meal with, I think, seven of our former students, and being taken to visit some of the villages in the surrounding area. I shall never forget a lady giving me one of her chickens as a thank you for visiting her humble home and being taken by Philippe to a pool inhabited by several alligators. One of them, about eight to ten feet in length, was basking in the sun on the edge of the bank. Although they were wild animals Phillippe persuaded me to approach it from behind while he threw it a chicken.  He then encouraged me to pick up its tail and I, not liking to appear not to trust him, cautiously did as he said. And there was no reaction from the animal! So I was able to tell the grandchildren what I had done and show them a photo to prove it, warning them never to anything so foolish! But actually it wasn't quite as foolish as it sounds. The alligators were indeed wild, but as Philippe explained to me, the people who were not yet Christians worshipped these animals and regularly brought them food. As a result they had become relatively tame. There was, of course, an element of danger – you never know what a wild animal might do – but they were, oxymoronically, tame wild animals! I am so grateful to the Lord not only for the privilege of visiting so many different countries and cultures, and for so many opportunities to be a blessing to so many people, but also for the fun I've had in doing so. And this was to continue for years after my retirement from Mattersey. But before that could happen a very important decision had to be made. Who was to be my successor? Next time I'll tell you how that decision was made.

Charlie Kirk was assassinated yesterday (2:30). Nicky Smokes tried to expense cigarettes on the Beach House (17:30). Dave gives a Fox update and how he feels Wake Up Barstool is doing (18:30). T-Bob and Kayce got hammered in front of Dave during a live stream (21:45). Dave wants to be the spokesman for Imodium (24:00) Mut joins the show to pitch a job at Barstool (27:30). Mut brings up the negatives (36:00). Chris Klemmer's reaction to Mut's pitch (41:00).You can find every episode of this show on Apple Podcasts, Spotify or YouTube. Prime Members can listen ad-free on Amazon Music. For more, visit barstool.link/unnamedshow

This week, the Meatballs are feeling bittersweet about their kids going back to school, replacing wine with THC drinks, and whipping themselves into shape. This episode is sponsored by: Blissy - Get better sleep, hair and skin with Blissy and use MEATBALL to get an additional 30% off at blissy.com/MEATBALL. Text or leave a voicemail for the Meatballs at (732) 508-7952 to get some Meatball Advice!

This week on Toilet Radio: Dave Mustaine announced that Megadeth is the latest in a long line of elderly metal bands to lie directly to our faces and say they're calling it quits. Sure thing, pal! Brett Hinds, formerly of Mastodon, is still watching old Mastodon performances on his phone late at night and commenting regrettable things. Mammoth Grinder is touring and it'll be the last one "for quite some time"? Kirk from Crowbar will need to perform sitting because his back is all junked to hell. The guy from Attila and the guy your 10-year old cousin watches on YouTube are beefing. Finally, Slipknot is selling their catalog for a reported $120 million dollars. How in the world does that make sense? We investigate! Music featured on this show: Feartilizer 1492 –Manifest of War Want more Toilet Radio? Get hundreds of hours of exclusive content and access to the TovH Discord over at the Toilet ov Hell Patreon. This program is available on Spotify. It is also available on iTunes or whatever they call it now, where you can rate, review, and subscribe. Give us money on Patreon to get exclusive bonus episodes and other cool shit.

Send us a textReal Housewives of Miami Season 7 Episode 5 Miami GodIn this episode of Real Housewives of Miami, Alexia seeks advice from a young self-help guru named Daniel, whom she found on Instagram. Despite his age, she feels he has wisdom and invites him to her upcoming Greek-themed "narcissist party," which she insists is not about her husband Todd—but actually about everyone in the group.Meanwhile, Lisa vents to Jody about her ongoing issues with Lenny and jokes that Larsa needs "Imodium for her mouth." Stephanie celebrates the success of her Shoma Bazaar business and opens up about her estranged twin sisters, who once worked with her but are now out of her life despite her attempts to reconnect. She's proud of her leadership role but doesn't exactly win over the audience with her delivery.Kiki, Larsa, and Stephanie have a heart-to-heart about family, encouraging Kiki to rebuild a relationship with her father for her son Shamar's sake. Shamar, notably, is the first in Kiki's family to go to college—a touching moment in an otherwise drama-filled episode.Guerdy, absent from Julia's baby shower, reveals that she was in New York ringing the bell at the Stock Exchange with the American Cancer Society. She feels misunderstood and ignored by the group. Alexia dismisses her feelings, ironically mirroring the same defensiveness she criticizes in Guerdy. Later, Guerdy meets with Julia, and the two have a tense but emotional conversation about broken trust. Julia accuses Guerdy of exposing her facelift secret while her wife was undergoing chemo, but Guerdy defends herself, saying she was only responding to Julia's energy. After hashing it out, they agree to move forward—slowly.Amid all the emotional reckonings, the cast prepares for a hurricane. Stephanie and her husband rescue puppies, while Lisa, unsurprisingly, shows up an hour and a half late to Alexia's event. The women wait for her for over two hours, which frustrates everyone, especially Stephanie, who openly calls her out. Lisa, for her part, shows no remorse. The party, complete with togas and philosophical speeches, wraps up the episode with lingering tension and plenty of side eyeTakeawaysGina expresses skepticism about Todd's commitment to his marriage with Alexia.Kelli and Gina discuss the financial dynamics of the cast members.The hosts share their opinions on the new cast member, Stephanie.Gina highlights the importance of family relationships in the show.Kelli mentions the upcoming BravoCon and its implications for the cast.The conversation reflects on the staged nature of the current season.Gina emphasizes the significance of genuine relationships among the cast.Kelli and Gina critique the production quality of the season.The hosts discuss the conflict between Gertie and Julia and its resolution.Kelli expresses her dislike for the character Stephanie, calling her a 'flex'.Support the showhttps://www.wewinewhenever.com/

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. Headed out for summer adventures? This week's Your Friday Five is your guide to creating a simple, powerful medicine travel kit—perfect for anyone on GLP-1s or just prone to nausea, headaches, or tummy trouble. Dr. Matthea shares what she personally packs (and rarely needs—but is always grateful to have!), including Tylenol, Pepcid, Zofran, Imodium, stool softeners, and even the trick of using alcohol pads for sudden nausea relief.She walks you through how to personalize your kit, when to involve your doctor, and why the smallest zip-top bag might just save your vacation.✈️ Keep this episode handy before your next trip!

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

Max Trescott interviews Dr. John Trowbridge, a physician and former senior Aviation Medical Examiner, to tackle a hidden yet critical safety topic: how over-the-counter (OTC) and prescription medications contribute to general aviation accidents. Studies have found that up to 40% of fatal accidents involve pilots with impairing substances in their system—ranging from allergy medications to sleep aids to alcohol. The problem? Many of these substances are legal and even commonplace, yet can significantly degrade judgment, memory, attention, and coordination. Dr. Trowbridge emphasizes that many pilots—and even their doctors—are unaware of FAA wait-time guidelines. He explains the FAA's “5x rule,” which states that a pilot must wait five times the recommended dosage interval before flying. So if a medication is taken every six hours, the pilot should wait 30 hours after the last dose. For 24-hour medications like Zyrtec, the wait time stretches to five full days. The discussion highlights the particular dangers of first-generation antihistamines like Benadryl (diphenhydramine), which are highly sedating and frequently found in sleep aids like Tylenol PM, NyQuil, and Unisom. These medications, even when taken the night before, can impair cognitive function well into the next day. Alarmingly, Benadryl is the most commonly detected OTC drug in fatal GA accidents. Dr. Trowbridge also warns about second-generation antihistamines like Zyrtec and Xyzal. While marketed as “non-drowsy,” these can still cause subtle sedation, especially in combination with alcohol or other medications. Alternatives like Allegra and Claritin are usually safer and FAA-approved—but only after personal ground-testing and AME consultation. Beyond antihistamines, they explore other drug categories. For pain relief, medications like aspirin, Tylenol, ibuprofen, and Aleve are generally safe, but anything with “PM” on the label likely contains sedating ingredients. Prescription painkillers like codeine are outright disqualifying. Dr. Trowbridge shares unconventional options too, like topical lidocaine, coconut oil, and even horse liniment—though with cautions about application and legality. Sleep aids are another minefield. Melatonin is the only one on the FAA's “go list,” and even it should be ground-tested first. Nasal decongestants such as Afrin and Sudafed can raise blood pressure and cause jitteriness, making natural remedies like saline rinses or cool vapor inhalation preferable. Cough medications also pose risks. Products with dextromethorphan (like DayQuil or Delsym) can sedate, as can multi-symptom formulas marked “PM” or “nighttime.” Gastrointestinal issues are more straightforward: most antacids like Tums and Maalox are safe, but anti-diarrheals like Imodium are not, due to sedation risks. UTIs are covered with non-sedating options like AZO and D-Mannose, but Dr. Trowbridge cautions pilots never to fly if symptomatic or on unfamiliar antibiotics. The conversation then turns to alcohol. The FAA's limit is 0.04%, but even lower levels can impair judgment, night vision, and reaction time—especially when combined with other medications or altitude-related hypoxia. Max cites an older FAA study showing that alcohol above 0.04% was found in 7% of fatal pilot crashes, with 3% involving both alcohol and drugs. Finally, Dr. Trowbridge emphasizes the importance of pilot self-awareness and due diligence. Most doctors are not trained in FAA regulations and may prescribe disqualifying medications unless reminded. He urges pilots to always research their medications, consult their AME, and even speak with pharmacists about interactions and cognitive side effects. Dr. Trowbridge's website, ClearedForTakeoff.info, offers in-depth presentations on pilot health concerns like sleep, sinus issues, inflammation, and safe alternatives to disqualifying drugs. His goal is to help pilots avoid both illness and medication risks, empowering them to stay flying—and stay safe. If you're getting value from this show, please support the show via PayPal, Venmo, Zelle or Patreon. Support the Show by buying a Lightspeed ANR Headsets Max has been using only Lightspeed headsets for nearly 25 years! I love their tradeup program that let's you trade in an older Lightspeed headset for a newer model. Start with one of the links below, and Lightspeed will pay a referral fee to support Aviation News Talk. Lightspeed Delta Zulu Headset $1299 Lightspeed Zulu 3 Headset $949Lightspeed Sierra Headset $749 My Review on the Lightspeed Delta Zulu Send us your feedback or comments via email If you have a question you'd like answered on the show, let listeners hear you ask the question, by recording your listener question using your phone. Mentioned on the Show Buy Max Trescott's G3000 Book Call 800-247-6553 Lightspeed Delta Zulu Headset Giveaway NTSB News Talk Podcast UAV News Talk Podcast Rotary Wing Show Podcast Dr. Trowbridge's website Dr. Trowbridge's book: The Yeast Syndrome FAA Go / NO List for Over-the-Counter Medications Free Index to the first 282 episodes of Aviation New Talk So You Want To Learn to Fly or Buy a Cirrus seminars Online Version of the Seminar Coming Soon – Register for Notification Check out our recommended ADS-B receivers, and order one for yourself. Yes, we'll make a couple of dollars if you do. Get the Free Aviation News Talk app for iOS or Android. Check out Max's Online Courses: G1000 VFR, G1000 IFR, and Flying WAAS & GPS Approaches. Find them all at: https://www.pilotlearning.com/ Social Media Like Aviation News Talk podcast on Facebook Follow Max on Instagram Follow Max on Twitter Listen to all Aviation News Talk podcasts on YouTube or YouTube Premium "Go Around" song used by permission of Ken Dravis; you can buy his music at kendravis.com If you purchase a product through a link on our site, we may receive compensation.

Not enough room, blue man group, photoshoots, and tummy issues. Charlie believes he knows how Hidden Valley Ranch got its start. A Rio Rancho high school baseball player peed into a water jug of the opposing team. Fourteen cars have been stolen from the airport. Shooting on the Las Vegas strip. Gianna turned 15 over the weekend. RMG+ is driving Rover crazy. Bankruptcy box. Rioters in LA take over the streets in an anti-ICE protest. JLR is fascinated by Maria Bartiromo. Duji is taking Imodium. Mixing wine with soda. The color of chicken eggs. Karen Read trial. Sneaking in to the Champions League Final. Charlie snuck onto Master P's trailer. Men wearing short shorts. Adobo. Woman at the weed store accidently tipped five thousand dollars.

Not enough room, blue man group, photoshoots, and tummy issues. Charlie believes he knows how Hidden Valley Ranch got its start. A Rio Rancho high school baseball player peed into a water jug of the opposing team. Fourteen cars have been stolen from the airport. Shooting on the Las Vegas strip. Gianna turned 15 over the weekend. RMG+ is driving Rover crazy. Bankruptcy box. Rioters in LA take over the streets in an anti-ICE protest. JLR is fascinated by Maria Bartiromo. Duji is taking Imodium. Mixing wine with soda. The color of chicken eggs. Karen Read trial. Sneaking in to the Champions League Final. Charlie snuck onto Master P's trailer. Men wearing short shorts. Adobo. Woman at the weed store accidently tipped five thousand dollars. See omnystudio.com/listener for privacy information.

Send us a textIn this episode, host Jessie Wong talks with Stacy, a past client who struggled with severe diarrhea, fatigue, and cramps due to IBS for over a decade. Discover how they worked together to identify Stacy IBS triggers and avoid unnecessary elimination diets, leading to complete symptom relief in just four weeks. Learn about why not everyone with IBS needs a low FODMAP diet and how proper symptom tracking and evidence-based guidance can transform your gut health journey.In This Episode, You'll Learn:✔ Stacy's battle with IBS symptoms since teenage years✔ Using Tums and Imodium – temporary fixes that didn't solve the root issue✔ How Stacy's GI doctor and working with a dietitian fit together✔ The trigger identification process (no low FODMAP required)✔ Life after IBS: freedom, symptom control, and no more bathroom emergencies✔ Stacy's top advice: Don't DIY restrictive diets – work with a proTimestamps:[00:00] Meet Stacy and her IBS journey [02:38] Life before IBS: symptoms since teenage years [04:14] Stacy's daily struggle: diarrhea, cramps, and exhaustion [07:33] Managing symptoms: Tums, Imodium, and frustration [12:43] Deciding to work with a dietitian for real answers [17:52] The truth about low FODMAP diets (and why Stacy didn't need it) [22:49] How we pinpointed Stacy's food triggers without going low FODMAP [28:10] Life today: symptom-free and confident [29:43] Stacy's advice for anyone with IBSResources Mentioned:Ep 18 With Bailey HannaEp 6 With Dr Andrea Love

Rover is in London. Did he last the whole the flight without pooping his pants? Showing ID for Imodium and a new fly stripper pole in the bathroom. Homeowners in Seattle are suing the city for alleged lewd acts being performed at Denny Blaine Park.

Rover is in London. Did he last the whole the flight without pooping his pants? Showing ID for Imodium and a new fly stripper pole in the bathroom. Homeowners in Seattle are suing the city for alleged lewd acts being performed at Denny Blaine Park. Marlins first baseman hit in the nuts by a ball. JLR got his tattoo done but did he tip? Spruce card update. $167 million dollar Powerball winner was arrested one day after his big win. Where is the first place JLR would travel to if he won the lottery? Shortage of air traffic controllers in New Jersey. Duji took a record player from Rover. Jeffrey is running sound effects. A small plane makes an emergency landing on a golf course. An AI generated picture of Donald Trump as The Pope is being shared. Is Krystle sad? Snitzer went to New York city. Rumor is Bill Belichick has been talking to a P.R. rep to help him after his awkward CBS interview. Duji feels bad for Bill Belichick's girlfriend Jordan Hudson.

Rover is in London. Did he last the whole the flight without pooping his pants? Showing ID for Imodium and a new fly stripper pole in the bathroom. Homeowners in Seattle are suing the city for alleged lewd acts being performed at Denny Blaine Park. Marlins first baseman hit in the nuts by a ball. JLR got his tattoo done but did he tip? Spruce card update. $167 million dollar Powerball winner was arrested one day after his big win. Where is the first place JLR would travel to if he won the lottery? Shortage of air traffic controllers in New Jersey. Duji took a record player from Rover. Jeffrey is running sound effects. A small plane makes an emergency landing on a golf course. An AI generated picture of Donald Trump as The Pope is being shared. Is Krystle sad? Snitzer went to New York city. Rumor is Bill Belichick has been talking to a P.R. rep to help him after his awkward CBS interview. Duji feels bad for Bill Belichick's girlfriend Jordan Hudson. See omnystudio.com/listener for privacy information.

Rover is in London. Did he last the whole the flight without pooping his pants? Showing ID for Imodium and a new fly stripper pole in the bathroom. Homeowners in Seattle are suing the city for alleged lewd acts being performed at Denny Blaine Park. See omnystudio.com/listener for privacy information.

These are some horror stories about Imodium....

In this episode of "Ditch the Lab Coat, where we delve into health issues with a grounded, scientifically skeptical eye. This week's conversation is truly special as we sit down with two giants in the field of medicine: Dr. David Carr and Dr. Sumon Chakrabarti. Join us as we unpack the essentials of travel medicine. From crafting the ultimate travel medical kit to knowing when to panic about that mysterious fever after your Southeast Asian adventure, these experts bring humor, experience, and a wealth of knowledge to the table. Whether you're planning a family vacation or a solo expedition, this episode promises to equip you with the wisdom you need to travel smart. Get ready to learn about must-have medications, the truth about travel vaccines, and how to handle those daunting, "Is there a doctor on board?" moments on a plane. Sit back, relax, and let us turn you into the savvy traveler you've always wanted to be. Let's get into it! and prepare to have your preconceptions about medicine and holistic care turned upside down.Episode HighlightsTravel Kits Essentials: Dr. Carr and Dr. Chakrabarti shared their must-have items for medical travel kits, including antiemetics like Zofran for nausea and glue (Dermabond) for minor injuries. They also discussed the importance of carrying Imodium for emergencies but warned against using it as a solution for diarrhea with fever.Medical Travel Tips: They emphasized preparing for potential health issues depending on the destination, especially in places with known diseases, such as malaria in certain regions. Pepto Bismol was highlighted as an effective preventive measure for traveler's diarrhea.Vaccination Advice: Dr. Chakrabarti recommended vaccinations based on the destination, particularly focusing on hepatitis A, typhoid, and yellow fever in certain regions. They also discussed the malaria prophylaxis options available today, like Malarone.Emergency Situations on Airplanes: Dr. Carr shared his experiences responding to medical emergencies on flights, describing the airplane's medical kits as adequate but limited, emphasizing the importance of an EpiPen and defibrillator.Healthcare Access While Traveling: They talked about how healthcare access varies by destination and shared personal stories of needing medical attention abroad, such as Dr. Bonta's trip to the Amazon.Safety Precautions: Emphasized no pills and no powders, especially for teenagers on trips. They suggested considering Narcan kits due to the prevalence of opioids tainting other substances and the importance of preventative measures like condoms to avoid STDs in areas with higher rates.Returning Traveler's Fever: Both guests stressed the importance of not dismissing a fever on returning from a tropical trip, as this could signify a serious condition like malaria.Episode Timestamps04:13 - Travel medical essentials insights.09:32 - Emergency eye and ear care prep.10:51 - Ducorel: Cholera vaccine limitations.14:33 - Plane medical emergencies: doctor's role?18:21 - Vaccine recommendations for Caribbean travel.20:46 - Essential travel vaccines and malaria prevention.22:56 - Avoiding travel health mistakes.27:27 - Check fever after tropical travel.31:45 - Essential travel health tips.32:41 - Gratitude and safe travels.DISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.       Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. 

From anxiety to how you should dress to how to budget! Do you pack the shower shot? Imodium? Lube? And what even is a sex convention about anyways!?! This week we do another deep dive into how we prep for events like Darklands! Its convention time! Mike:Bluesky: https://bsky.app/profile/mikestabile.bsky.socialFSC: https://bsky.app/profile/fsc.bsky.social— VIIA: 21+, Try VIIA Hemp THCV! https://bit.ly/viiawatts and use code WATTS for 25% OFF (and 50% off certain bundles this week)!! —— Over 2 Million Butts Love TUSHY. Get 10% off TUSHY with the code WATT at https://hellotushy.com/watt #tushypod —- Watts Socials -Discord: https://discord.gg/bxqDQVcKH7Amps Linktree: https://linktr.ee/pupampKristofer Linktree: https://linktr.ee/mrkristoferSAFEWORD MERCH: http://www.safewordshop.comTWITCH: http://twitch.tv/wattsthesafewordWatts Your Safeword Podcast:Itunes: http://apple.co/2QkMDwkSpotify: http://spoti.fi/2QjPNjLTwitters:http://twitter.com/WattsTheSafewrdhttp://twitter.com/PupAmphttp://twitter.com/kristoferwestonInstagrams:https://instagram.com/PupAmp/https://instagram.com/mrkristoferwestonhttps://instagram.com/wattsthesafewordFacebook: http://ow.ly/Z5nvMPatreon: https://www.patreon.com/WattsTheSafewordOpening by the magical Aethernaut https://aethernaut.bandcamp.comMusic by Joakim Karud http://youtube.com/joakimkarud

This one is definitely not for Max. Producer Ryan, Mulls, Bryce, and Rog discuss some Rock Island memories, Bryce's Imodium situation, and plenty more. Holy hecka, this one is one of the greats.

Jay hosts Smarty and Luke in this weeks main pod recording Hosted on Acast. See acast.com/privacy for more information.

Hoy escuchamos: Dream Theater- A broken man, Accept- Humanoid, Rhapsody of Fire- Challenge the wind, Saurom- El principito, Dynazty- Game of faces, Alestorm- Voyage of the dead Marauder, Ankhara- Tu verdad, Nanowar of Steel- The power of Imodium, Angelus Apatrida- Cold, Meshuggah- The abysmal eye, Vita Imana- Adversario.Escuchar audio

The Problem: None of them has produced any bad. Merlin wants to play in this band. (Recorded on Monday, November 11, 2024.) Support Roderick on the Line on Patreon.

Send us a textBobby and Jim are back from Puerto Vallarta, celebrating Bobby's 40th birthday in true chaotic fashion. From forgotten weed gummies to full blackouts in gay pool parties, the episode takes you on a wild journey. Highlights include Bobby's panic over leaving his weed gummies at home, several intense discussions about aging, and multiple bottoming revelations. They also reflect on their peak moments at Montemar, stories about a threesome with a cartel-adjacent daddy, and detailed escapades in the streets of PV, where they embraced their inner brat spirit. The episode dives into everything from tequila-fueled threesomes, hangover guacamole, the oddities of traveling, and new life philosophies like "Imodium before sex." The narrative gets both spicy and reflective, with Bobby deciding to make the most of his "daddy peak" and discussing the circle of life at Montemar.The chaotic pace is matched by snarky asides, irreverent observations on straight culture, and a whole lot of self-deprecating humor. Expect tons of outrageous stories about everything from nearly doing meth to deep discussions about belly buttons.Support the showAs always you can write us at nowellpodcast@gmail.com or call us at ‪(614) 721-5336‬ and tell us your Not Wells of the week InstagramTwitterBobby's Only FansHelp us continue to grow and create amazing content, like a live tour or just help fund some new headphones when needed. Any help is appreacited. https://www.buzzsprout.com/510487/subscribe#gaypodcast #podcast #gay #lgbtq #queerpodcast #lgbt #lgbtpodcast #lgbtqpodcast #gaypodcaster #queer#instagay #podcasts #podcasting #gaylife #pride #lesbian #bhfyp #gaycomedy #comedypodcast #comedy #nyc #614 #shesnotdoingsowell #wiltonmanor #notwell

Thru hiker, Renaissance Man, and Vice President of Six Moon Designs, Whitney "Allgood" La Ruffa drops in from his world travels to talk trail and share some very exciting news with Doc. Settle in and buckle up as Allgood takes Doc on a rollicking conversation, including discussions of Adventure Trekking, All Day Carry, not hating yourself, seeing the world at human speed, adventures with too much chili and no Imodium, expectations, Idaho hiking, trail legends, becoming a Hiker Trash Radio Triple Crowner, and, of course, Nature's Wet Wipe. Hilarious. Learn more about your ad choices. Visit megaphone.fm/adchoices

Luke's crowned himself a born hustler after his recent forays into the world of Facebook Marketplace. Elsewhere, Pete tells us how his nan stole Churchill's thunder with a bassinet full of babies.Plus, has Sammy shit on the floor in sympathy for Donny's week of having the runs?Email: hello@lukeandpeteshow.com or you can get in touch on Twitter or Instagram.***Please take the time to rate and review us on Apple, Spotify or wherever you get your pods. It means a great deal to the show and will make it easier for other potential listeners to find us. Thanks!*** Hosted on Acast. See acast.com/privacy for more information.

Secret Week – Woody's Mum has a secret John Edwards We test Customer Service Do planes put Imodium in food See omnystudio.com/listener for privacy information.

LA City Council votes to bolster ability to monitor, potentially regulate self-driving vehicles // the greater LA area has the worst potholes and roads // KTLA's Sam Rubin to posthumously receive Governors Award at L.A. Area Emmys // Tim would give the guys that invented Pepto Bismol and Imodium deserves a star on the walk of fame // Stefoosh inspires kindness with his grocery store story // 25 pro-Palestinian protesters arrested at UCLA, ordered to stay away from campus 

We welcome back to the show, Tony Schwartz. A former columnist for The New York Post, and associate editor at Newsweek, he was also a reporter for The New York Times, and staff writer at New York Magazine and Esquire. In 1985, Schwartz began interviewing Donald Trump to ghostwrite Trump: “The Art of the Deal” for which he was given co-author credit. Art of the Deal was published in 1987 and some say it's what sold Trump to the public as a successful businessman. Tony is here today to talk about how Trump ticks and just how traumatizing his current legal predicaments are bound to be. Learn more about your ad choices. Visit megaphone.fm/adchoices

1:05 Pre Show Shouts.  3:35 Get a load of Sabien.  10:15 What if you ran out of batter.  12:02 Having Baby's at 90.  14:06 going air tight.  21:20 Imodium farts are death.  23:11 F2F Ambassador.  27:15 content freedom on OF.  32:20 Finding love of Kink.  35:05 Loves Public Hookups.  36:02 Disputed questions.  47:25 Eating the whole chicken.  49:55 JDub's Questions.  55:48 Sabien Beats up her 19 year old self.  57:22 Conspiracy theories. 1:00:45 Betty Page. 1:03:34 the most important question there is. 1:11:12 Hitting the Road.    Welcome to the Working Perspectives Podcast Hosted by:  Matt Lavelle and Justin Richardson Featuring:  Sabien DeMonia Working Perspectives Podcast Links:  https://www.tiktok.com/@workingppod?lang=en https://www.instagram.com/workingperspectivespodcast/ https://www.facebook.com/workingperspectivespodcast-100884222318497 https://twitter.com/workingppod https://linktr.ee/Workingperspectives   Sabien DeMonia Links:  https://twitter.com/Sabien_DeMonia https://www.instagram.com/sabiendemoniaofficial https://www.youtube.com/c/SabienDeMonia https://linktr.ee/CumAndGetMe   ABOUT SABIEN DEMONIA Eastern European tatted, busty, red-haired vixen Sabien DeMonia is a content creator, fetish model, adult star, and entrepreneur. Known for her wild scenes, GG breasts, and her even bigger attitude, she's definitely one to watch. She started doing live studio and cam shows for Babestation in the UK. Once Sabien took it to the next level, she worked for some of the most extreme Euro and US studios, including Evil Angel, Fake Hub, Canal +, Alt Erotic, Fake Taxi, Marc Dorcel, Reality Lovers, Czech VR, VR Taboo, Perverse Family, Bikini Fanatics, Legal Porno, Lust Reality, Gonzo.com, AltPorn4U, and more. Over the past few years, she scored a contract with Kink.com as director and contract star and had her own self-titled channel on Adult Time. In just four years, Sabien's become very well known in and out of the adult industry and scored countless magazine covers and features for worldwide publications like FHM, XBIZ, Hustler, B.A.D.D., Bubble Shake, Inked Barbie, Kink Queens, Femme Rebelle, Tattoo Planet, Tattoo Kultur, Kinkd, and more. In 2023, her worldwide fans fell in love with her FHM Canada and Bulgaria covers and features and Playboy New Zealand, Norway, and Kazakhstan branded her a Playboy Playmate. She's won awards for Creator Brand Ambassador of the Year in the XBIZ Executive Awards, Best Overall Model and Best Porn-Cam Model from Spain's Ero Awards, Fetish Model of the Year from UK Glamour Awards, Gonzo Performer of the Year and Jury Prize for Best Webcam Celebrity from the Venus Awards, Clip Artist of the Year and the Bucharest Summit Recognition Award from the Bucharest Summit Awards, Best Clip Artist and Best Live Cam Celebrity of Year from the Live Cam Awards (twice), Best Gonzo AltPorn Video, Best Gothic Shoot, and Best Inked Clip from the AltStar Awards, and MV Munkbung Vid of the Year from the ManyVids Community Awards. Sabien has received numerous nominations from XBIZ Europa, XBIZ Creator, AVN, AltStar, Bucharest Summit, Live Cam, BCAM, Fleshbot, Inked, UK Fetish, and Venus Awards. She's a Brand Ambassador for Hotline, Pineapple Support, and Gaming Adult's Hentai Heroes, and previously was the first official Cherry.tv Ambassador, as well as representing xxxNifty and SugarBounce.

Please Subscribe and Review: Apple Podcasts | RSS Submit your questions for the podcast here News Topic: Recent advances in the exploration and discovery of SARS-CoV-2 inhibitory peptides from edible animal proteins   Questions:    Too much cardio for diabetes?  Thomas writes: Hi Robb and Nicki, second time questioner with an answer on the first question. First was about long term Imodium use. I am one of the six who truly appreciate what you do and listen all the time. I'm also an LMNT believer. This one is for my mother in law. She has controlled diabetes with diet and exercise for years. I would say they are Paleo on the lower end of protein. Now her A1C and fasting glucose are going up. Lots of walking and biking (weather permitting on the biking). Walking upwards of 7-10 miles a day. Could this be causing her body to produce more glucose for energy if protein is low or is her time up and leading towards insulin after all these years. Would weights be a benefit? Failed to mention she is in her low 70's and pretty small framed.   Junk food calories - can the junk be burned?  Caleb writes: Howdy Robére and Nikki, I'm an OG supporter that came across you all while I was working for one of the first Whole30 approved products, Tessemae's All Natural. I've been to a handful of PaleoFX events and my last one was a few years back where we connected at the LMNT booth and I just want to extend my appreciation for you two staying true to real food and nuanced information without turning into sh*thead snake oil salesman selling Beauty Counter or other garbage products like the majority of the old "real food influencers". I recently started ultra training and found that if I use whole foods for all my fuel I end up with a giant rock in my stomach and occasionally have to sprint off trail to test my below 90 degree wall sits on a tree to relieve myself. I've since gone towards gu's and swedish fish for my training and race fuel and the rest of my calories come from lean red meat, fruits, japanese sweet potatoes, avo oil, ghee, and trace amount of calories from a little slice of heaven called LMNT (plug). My digestion is great, my stool is strong, my skin is clear(ish. I always have trouble with acne), and my energy is solid. I just want to make sure I'm not causing any long term issues by crushing swedish fish, gu's, and chilled peanut m&ms during training and wondering if the fact that I'm currently a furnace for calories, if that furnace burns the "bad" stuff in processed foods along with the calories themselves. Stay salty, C   Weight Loss and Maintenance Jenn writes:  Hi Robb & Nikki, I want to start by first saying thank you for the entertaining and informative podcast as well as the delicious electrolytes! My question today is related to weight loss and how to potentially move that needle. Sorry for the long winded story and question! I'm a 34 year old female 5'7" and 175 pounds. I have a desk job, but I am active every day. I box/kickbox twice a week, crossfit once a week, swim laps once a week, practice yoga/mobilty several times a week, strength train at least once a week (aim for 2-3x) and I walk between 7 & 10,000 steps every day. I have in the past lost weight doing chronic cardio and extreme calorie restriction, and I have reached 155 pounds, which is where I feel the best (confidence and energy wise), but of course, once I stop the extreme dieting and exercise, the weight comes back on. At my heaviest I was 215 pounds but I am able to maintain 175 very easily now, but getting that last 15-20 pounds off and keeping them off is a major struggle. Peter Attia has said that your waist should be half of your height or less, so at 5'7", my waist should 33.5" and I'm at 37" and it will not budge. I eat a very clean diet, following Paul Saladino' animal based framework - beef, eggs, chicken, apples, blueberries, hard cheeses (parmesan and old cheddar), potato, carrots, squash, sauerkraut, mangos, bananas etc. and I follow Dr. Mindy Pelz's intermittent fasting framework. Chronometer shows that I'm eating between 140-160g of protein, 50-150g of carbs and the remaining calories are fat, and on average I'm eating between 1800-2000 calories a day and feel satiated. Taking my activities into account, I have between a 250 and 500 daily calorie deficit which means that I should be losing weight at a slow, steady pace, but I'm not. I'm wondering if my hormones are possibly causing a problem? I have regular bloodwork done and my thyroid levels are in normal range and my fasting glucose is 4.6 mmol/L and all other markers are normal. A problem is that I live in the socialist country of Canada and my doctor won't test my hormones because of my age and the fact that I don't have any health issues and I'm not obese (preventative healthcare does not exist). I've tried to look at CGM's and private hormone testing, and each of those will put be out of pocket between $500 and $1000, which is more than I can afford at the moment. I try not to overdo the fasting and exercise so as not to increase cortisol levels too much, I do have a stressful job and I purposefully take a break in the middle of the day to go for a walk or exercise to help keep those stress levels under control. I try to get outside for at least 30 minutes a day (not always possible due to the weather) and I get between 7.5 and 8 hours of sleep a night - usually good quality sleep but I do have the occasional restless night. The supplements I take besides LMNT are magnesium, Vitamin D and CBD. My only vices are coffee and tea, which I drink black or with a small amount of honey or coconut milk. I feel like I'm doing everything right, I feel healthy and have a great partner and life but I just can't seem to get the weight under control. Do you have any thoughts or suggestions that may help me to move the needle and keep the weight off for good? Or am I worrying over something that is not a big deal? I want to be as healthy and strong as I can be going into my mid-life years. Appreciate any thoughts you may have. Jenn Sponsor: The Healthy Rebellion Radio is sponsored by our electrolyte company, LMNT. Proper hydration is more than just drinking water. You need electrolytes too! Check out The Healthy Rebellion Radio sponsor LMNT for grab-and-go electrolyte packets to keep you at your peak! They give you all the electrolytes want, none of the stuff you don't. Click here to get your LMNT electrolytes Transcript: Coming soon...

With several reports of Benadryl and Imodium abuse, Officer Jermaine Galloway expresses the importance of knowing safe doses. Due to online trends, the cheap cost, and easy accessibility, over-the-counter substances have become an epidemic all around. It's no longer typical abusers but kids and alcoholics too.

Dr. Mark Pimentel discusses New Research Findings on SIBO and IBS at the Functional Medicine Discussion Group meeting on May 25, 2023 with moderator Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.]    Podcast Highlights 4:24  Dr. Pimentel started a fellowship at Cedars in 1996 on motility and his colleagues questioned why he would want to get involved with treating IBS patients, who are psychologically altered?  Patients with IBS seemed like regular folks who were struggling and it is too easy to attribute medical conditions that are not well understood to psychological causes. He reflected on when heart disease was thought to be primarily due to stress and in the early 70s if you had a heart attack, you were told that you needed to quit your job.  But it turned out that what caused their heart attack was more due to the steakhouse with the cholesterol and the alcohol and the smoking and your genetics and all the other things we learned about cardiovascular disease.  One of his colleagues in 1996 told him that "IBS is a disease of hysterical women." 5:41  Anti-diarrheals.  Even in the last three years, the AGA guidelines say that anti-diarrheals like Imodium should be first-line therapy for irritable bowel syndrome because they're cheap.  This is not a good reason to recommend a medication, rather than trying to figure out the cause of IBS and then treating that.  This is because the research that Dr. Pimentel has conducted and published for the last 26 years that demonstrates that SIBO is the main cause of IBS has still not been fully accepted by the GI community.  6:36  Food poisoning is the cause of about 60% of cases of IBS-D and there is now enough research data to prove this.  The bacteria that cause food poisoning, whether it be E. coli or Campylobacter or Shigella or Salmonella secrete an endotoxin--Cytolethal Distending Toxin (CDT) and specifically the B version of CTD--CDTB--that leads to SIBO/IBS.  The immune system reacts to the CDTB and those anti-CDTB antibodies end up cross reacting with a structural protein in the intestinal wall called Vinculin.  Thus the immune system is attacking the body, an auto-immune reaction.  This leads to damage of the nerves that control the intestinal cleansing waves, which leads to a buildup of the bacteria in the small intestine (SIBO).  These small intestinal cleansing waves are peristaltic waves that are occur when you haven't eaten for more than 3 or 4 hours, which help to clear out excess bacteria.  These cleansing waves are caused by the deep muscular plexus-interstitial cells of Cajal.  Dr. Pimentel has developed a second generation test that measures antibodies to CDTB and to vinculin via blood testing that is extremely accurate, the IBS Smart test from Gemelli Biotech.  25:37  Methane SIBO (IMO) does not appear to be caused by food poisoning.  By paralyzing the gut in the case of hydrogen and hydrogen sulfide SIBO, this can lead to diarrhea. In the case of methane, this causes the gut to hypercontract and this overcontraction of the gut muscles leads to constipation. 29:33  In a study published in 2020 Dr. Pimentel's group showed that a lactulose breath test--not a glucose breath test--and using the 90 minute cutoff of more than 20 parts per million increase in hydrogen it correlated well with the bacteria in the gut seen in culture and the hydrogen-producing enzyme machinery in the small intestine was elevated.  This shows that the hydrogen is being produced in the small intestine and not in the colon. (Leite G, Morales W, Weitsman S, Celly S, Parodi G, Mathur R, Barlow GM, Sedighi R, Millan MJV, Rezaie A, Pimentel M. The duodenal microbiome is altered in small intestinal bacterial overgrowth. PLoS One. 2020 Jul 9;15(7):e0234906.)

In this episode, I discuss loperamide (Imodium) pharmacology, adverse effects, and drug interactions. Loperamide has opioid-type activity in the gut but has extremely low oral bioavailability. This allows it to be used for diarrhea but at lower doses won't cause systemic opioid-like effects. Loperamide abuse has been reported. Excessive dosages can increase the risk of cardiac arrest and other cardiovascular concerns. Medication causes of diarrhea should be ruled out prior to starting a medication like loperamide. I discuss numerous medications that can cause diarrhea in this podcast.

The girlies uncover the complicated history of the American nail salon — from the wave of Vietnamese immigration that kick-started the industry to the toxic chemicals and labor violations that lay below the surface. Digressions include a call for a REPUTABLE pet psychic, the deeply spiritual significance of Imodium, and our current Godly Wife name fixations. Support the podcast on Patreon at patreon.com/binchtopia. SOURCES:From 3200 B.C. to Today: The Fascinating History of Nail Polish Cutex Hooked Americans on Manicures Celluloid Dreams: The Marketing of Cutex in America, 1916-1935 Author(s): Kate FordeThe Making and Transnationalization of an Ethnic Niche: Vietnamese Manicurists by Eckstein and Nguyen Nail salon workers exposed to high levels of toxic chemicals, new study reveals Nail salon workers say proper ventilation can protect their reproductive healthPerfect Nails, Poisoned WorkersThe Price of Nice Nails Nail salon sweeps in New York reveal abuses and regulatory challenges How Black Women Pioneered Nail Art Manicuring Race, Gender, and Class: Service Interactions in New York City Korean-owned Nail Salons by Miliann Kang Hosted on Acast. See acast.com/privacy for more information.

Leave a voicemail for Dr. Drew to answer on the show at (818) 253-1693 or email your question to DrDrewAfterDark@gmail.com. This week on Dr. Drew After Dark we have co-host of Wide World Of Dougs podcast and comedian, Doug Mellard! Doug tells Drew how he got into comedy in college by pulling all sorts of pranks on strangers for his own amusement. Turns out he founded the Nicole Kidman Foundation at University of Texas, Austin to advocate on the actress's behalf when she split up from Tom Cruise. We take some medical related listener questions about nose bleeds, side effects of diabetes, weight loss, and long term Imodium use. We then take a look at some cool guys giving diet advice, threatening sales people, and filming a film crew in public. We then wrap up with taking some more brown related fan questions. https://drdrew.com/https://store.ymhstudios.com/